Pro-inflammatory cytokine and chemokine signaling

Pro-inflammatory cytokine and chemokine signaling refers to a broad and complex network of molecular interactions that coordinate the body's response to injury and infection. This pathway involves the production and release of signaling proteins, such as tumor necrosis factor (TNF), interleukins (IL-1, IL-6), and various chemokines, which bind to specific cell-surface receptors to initiate intracellular cascades like the NF-κB and JAK-STAT pathways (Source: Nature Reviews Immunology). While essential for host defense, chronic or excessive activation of these signals is a primary driver of tissue damage in autoimmune diseases like rheumatoid arthritis, inflammatory bowel disease, and psoriasis (Source: Frontiers in Immunology). Therapeutic strategies often focus on highly specific components of this signaling network, such as neutralizing antibodies against TNF-α or small-molecule inhibitors of signaling kinases (Source: Journal of Clinical Investigation). Because this entry describes a broad biological process rather than a single protein or receptor, it is classified as a pathway rather than a discrete therapeutic target (Source: IUPHAR/BPS Guide to Pharmacology). Clinical management of this pathway requires a balance between suppressing pathological inflammation and maintaining sufficient immune surveillance to prevent opportunistic infections (Source: The Lancet).

Other names

Inflammatory signaling pathwayCytokine-mediated signalingChemokine-mediated signalingPro-inflammatory cascade

Drugs targeting this pathway typically act through ligand neutralization (monoclonal antibodies), competitive receptor antagonism, or the inhibition of downstream intracellular signaling enzymes such as Janus kinases (JAKs) (Source: Nature Reviews Drug Discovery).